RGNX

REGENXBIO Inc. (NASDAQ:RGNX) is a clinical-stage biotechnology company founded in 2008 and headquartered in Rockville, Maryland. The company went public in September 2015 and has established itself as a leading developer of gene therapies based on its proprietary NAV Technology Platform, which utilizes adeno-associated virus (AAV) vectors to deliver therapeutic genes to cells. REGENXBIO focuses on developing treatments for genetic diseases and conditions where cells need to produce therapeutic proteins or antibodies. The company has built a robust pipeline of gene therapy candidates targeting various rare diseases, with several programs advancing through clinical trials toward potential regulatory approval.